Show document

A+ | A- | | SLO | ENG

Title: S100 B - tumorski označevalec kožnega melanoma Authors: ID Perić, Barbara (Author) ID Žagar, Ivana (Author) ID Novaković, Srdjan (Author) ID Žgajnar, Janez (Author) ID Hočevar, Marko (Author) Files: PDF - Presentation file, download (159,52 KB) MD5: A7CF74760143DBC4B58FD8B63937DC73 PID: 20.500.12556/dirros/86de4062-8d47-4c7f-b729-dbee48c9b16d   Language: Slovenian Typology: 1.03 - Other scientific articles Organization: OI - Institute of Oncology Abstract: Da bi pravočasno odkrili zasevke kožnega melanoma (KM), na Onkološkem inštitutu Ljubljana uporabljamo določanje serumske ravni tumorskega označevalca S100B. Če je raven zvišana, nadaljujemo s slikovnimi preiskavami, v zadnjih letih predvsem s PET-CT. S svojo raziskavo smo skušali pokazati, kako učinkovito je odkrivanje napredovale bolezni z določanjem serumskega S100 B in s PET-CT med rednim sledenjem bolnikov, ki imajo KM. Med septembrom 2007 in februarjem 2010 smo na PET-CT napotili 115 bolnikov s KM. Med njimi je bilo 82 (71,3 %) bolnikov s kliničnimi znaki bolezni in 33 (28,7 %) asimptomatskih bolnikov z 2 povečanima vrednostma serumskega S100 B. Z uveljavljenimi metodami smo izračunali občutljivost, specifičnost ter pozitivno in negativno napovedno vrednost (PNV, NNV) določanja S100 B in PET-CT. Zasevke smo odkrili pri 81,7 % bolnikov. Občutljivost, specifičnost, PNV in NNV S100 B so bili 33,8 %, 90,9 %, 96 % in 17,5 % pri bolnikih s kliničnimi znaki bolezni. Pri 20 % bolnikov so bile povečane serumske vrednosti S100 B edini znanilec zasevkov KM. Občutljivost in PNV S100 B v tej skupini bolnikov sta bila 100 % in 69,7 %. S PET-CT smo napredovalo bolezen potrdili pri 84,2 % bolnikov, ki so imeli klinično sliko napredovale bolezni, ter pri 72,7 % asimptomatskih bolnikov s povečanimi vrednostmi S100 B. Občutljivost, specifičnost, PNV in NNV PET-CT za bolnike s klinično sliko so bili 98,5 %, 90,9 %, 98,5 %, 90,9 % ter 100 %, 90 %, 95,8 % in 100 % pri asimptomatskih bolnikih s povečanimi vrednostmi S100 B. Redno spremljanje serumskega S100 B pri bolnikih s KM omogoča odkritje napredovale bolezni pri asimptomatskih bolnikih. Uspešnost metode je večja, če bolnike napotimo na PET-CT, kadar imajo povečane vrednosti S100 B. Publication status: Published Publication version: Version of Record Year of publishing: 2011 Number of pages: str. 102-105 Numbering: Letn. 15, št. 2 PID: 20.500.12556/DiRROS-8759  UDC: 616.5-006.6-076 ISSN on article: 1408-1741 URN: URN:NBN:SI:doc-DCCLDDHW COBISS.SI-ID: 1196411  Copyright: by Authors Note: Soavtorji: I. Žagar, S. Novaković, J. Žgajnar, M. Hočevar; Publication date in DiRROS: 31.08.2018 Views: 4424 Downloads: 931 Metadata:    Cite this work Plain text BibTeX EndNote XML EndNote/Refer RIS ABNT ACM Ref AMA APA Chicago 17th Author-Date Harvard IEEE ISO 690 MLA Vancouver : Copy citation

Share: Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:	Onkologija
Shortened title:	Onkologija
Publisher:	Onkološki inštitut
ISSN:	1408-1741
COBISS.SI-ID:	65324032

Licences

License:	CC BY 4.0, Creative Commons Attribution 4.0 International
Link:	http://creativecommons.org/licenses/by/4.0/
Description:	This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:	31.08.2018

Secondary language

Language:	English
Title:	S100B – Tumor marker in cutaneous melanoma
Abstract:	Introduction. An increased level of serum S100B can serve as a marker of metastatic spread in patients with cutaneous melanoma (CM). In patients with elevated S100 B and/or clinical signs of disease progression, a PET-CT scan is a valuable tool for discovering metastases and planning treatment. The aims of this study were to determine whether regular measurements of serum S100B are a useful tool for identifying patients with CM metastases and for evaluating the diagnostic value of PET-CT during the follow-up. Methods. From September 2007 to February 2010, 115 CM patients included in regular follow up at the Institute of Oncology Ljubljana were appointed to receive PET-CT scans. They included 82 (71.3%) patients with clinical signs of disease progression and 33 (28.7%) asymptomatic patients with two subsequent elevated values of S100B. Sensitivity, specificity, positive and negative predictive values (PPV, NPV) of S100B and PET-CT were calculated using standard procedures. Results. Disease progression was confirmed in 81.7% of the patients (in 86.5% of patients with clinical signs of disease progression and in 69.7% of asymptomatic patients with elevated S100B). Sensitivity, specificity, PPV and NPV of S100B was 33.8%, 90.9%, 96.0% and 17.5%, respectively, in patients with clinical signs of disease progression. For 20.0% of the patients increased serum S100B was the only sign of disease progression. Sensitivity and PPV of S100 in this group of patients were 100.0% and 69.7%, respectively. PET-CT disease progression was diagnosed in 84.2% of symptomatic patients and in 72.7% of asymptomatic patients with elevated S100B. The sensitivity, specificity, PPV and NPV of PET-CT for symptomatic patients was 98.5%, 90.9%, 98.5% and 90.9%, respectively, and 100%, 90.0%, 95.8% and 100%, respectively, for asymptomatic patients with elevated S100. Conclusions. Measurements of serum S100B during regular follow-up of patients with CM are a useful tool for discovering disease progression in asymptomatic patients. The value of its use increases if measurements are followed by extended whole body PET-CT.

Archive

niGradiv

Back